Document is current
Any future updates will be listed below
-
Authors
Bojesen, Kirsten Borup https://orcid.org/0000-0002-7996-3154
Ambrosen, Karen S. https://orcid.org/0000-0002-5638-2357
Sigvard, Anne Korning
Nielsen, Mette Ødegaard
Gjedde, Albert
Kumakura, Yoshitaka
Jensen, Lars Thorbjørn
Fuglø, Dan https://orcid.org/0000-0002-8926-3549
Ebdrup, Bjørn Hylsebeck https://orcid.org/0000-0002-2590-5055
Rostrup, Egill
Glenthøj, Birte Yding https://orcid.org/0000-0003-3056-7262
-
Funding
Funding for this research was provided by:
PhD grant from the Faculty of Health and Medical Sciences, University of Copenhagen and Post doc grant from the research Fund 2022 in the Capital Region of Denmark
PhD grant from Mental Health Services in the Capital Region of Denmark
- License Information
-
More Information
Article History
Received: 12 January 2025
Revised: 2 August 2025
Accepted: 29 August 2025
First Online: 12 September 2025
Competing interests
: Dr. Glenthøj has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009 – December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. She has no other conflicts to disclose. Dr. Bojesen received lecture fees from Lundbeck Pharma A/S. Dr. Ebdrup BE is part of the Advisory Board of Boehringer Ingelheim, Lundbeck Pharma A/S; and has received lecture fees from Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, and Lundbeck Pharma A/S. The rest of the authors have no conflicts of interest to disclose.
